- IGC already has seven provisional filings for phytocannabinoid-based combination therapies
- Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs
India Globalization Capital, Inc. (NYSE American: IGC) anticipates filing, in 2018 and 2019, for international Patent Cooperation Treaty (“PCT”) patents, as well as U.S. national patent filings, for a portfolio of drugs (http://ibn.fm/Ncgz0).
Its drug for the treatment of Alzheimer’s (IGC-AD1) is anticipated for patent filings in PCT and the U.S. in 2018. Its seizure drug (IGC-505) is scheduled for filing for a U.S. patent in late 2018. The company’s eating disorders drug (IGC-504) is anticipated for filing for a U.S. patent late this year, while another eating disorders drug (IGC-506) is anticipated for filing for a PCT patent in 2018 and a U.S. filing in 2019. This portfolio encompasses the company’s drugs that are formulated to treat seizures, Alzheimer’s and eating disorders — representing large domestic and international markets.
For its drug formulated to treat Alzheimer’s, as described in a SeeThruEquity update on IGC (http://ibn.fm/5fBi8), it has formulated a cannabis-based combination which treats endpoints of the disease such as plaques, tangles, anxiety and agitation. IGC plans to market its patent-pending drug through U.S. and Canadian medical dispensaries in early 2018. A key goal for the company in 2018 is to get its lead product formulation, Hyalolex, ready for phase IIB human trials. IGC estimates that Alzheimer’s disease costs the U.S. economy alone roughly $236 billion annually. It affects more than 5.3 million Americans, and more than 65 percent of its patients are women.
IGC is a Maryland-based company with two lines of businesses. One is legacy, which includes the rental of heavy equipment, real estate management and commodities trading. The second is canna-pharmaceutical. That business is focused on developing a formulation using cannabis extracts for the treatment of many diseases.
For more information, visit the company’s website at www.IGCInc.us
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
